Franziska S Rathjens1,2, Alica Blenkle1, Lavanya M Iyer1,2, Anke Renger3, Fahima Syeda4, Claudia Noack1,2, Andreas Jungmann5,6, Matthias Dewenter6,7, Karl Toischer8, Ali El-Armouche9, Oliver J Müller10, Larissa Fabritz4,11,12, Wolfram-Hubertus Zimmermann1,2,13, Laura C Zelarayan1,2, Maria-Patapia Zafeiriou1,2,13. 1. Institute of Pharmacology and Toxicology, University Medical Center, Goettingen, Germany. 2. DZHK (German Center for Cardiovascular Disease), partner site, Goettingen, Germany. 3. Institut für Erziehungswissenschaften, Humboldt University, Berlin, Germany. 4. Institute of Cardiovascular Science, University of Birmingham, Birmingham, UK. 5. Internal Medicine III, University Hospital Heidelberg, Heidelberg, Germany. 6. DZHK (German Center for Cardiovascular Disease), partner site Heidelberg/Mannheim, Germany. 7. Department of Molecular Cardiology and Epigenetics, University of Heidelberg, Germany. 8. Department of Cardiology and Pneumology, University Medical Center, Goettingen, Germany. 9. Department of Pharmacology and Toxicology, Faculty of Medicine, University of Technology-Dresden, Germany. 10. Department of Internal Medicine III, University of Kiel, Kiel, Germany. 11. Division of Rhythmology, Department of Cardiovascular Medicine, Hospital of the University of Münster, Münster, Germany. 12. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. 13. Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells" (MBExC), University of Goettingen, Germany.
Abstract
AIMS: Arrhythmias and sudden cardiac death (SCD) occur commonly in patients with heart failure. We found T-box 5 (TBX5) dysregulated in ventricular myocardium from heart failure patients and thus we hypothesized that TBX5 reduction contributes to arrhythmia development in these patients. To understand the underlying mechanisms, we aimed to reveal the ventricular TBX5-dependent transcriptional network and further test the therapeutic potential of TBX5 level normalization in mice with documented arrhythmias. METHODS AND RESULTS: We used a mouse model of TBX5 conditional deletion in ventricular cardiomyocytes. Ventricular (v) TBX5 loss in mice resulted in mild cardiac dysfunction and arrhythmias and was associated with a high mortality rate (60%) due to SCD. Upon angiotensin stimulation, vTbx5KO mice showed exacerbated cardiac remodelling and dysfunction suggesting a cardioprotective role of TBX5. RNA-sequencing of a ventricular-specific TBX5KO mouse and TBX5 chromatin immunoprecipitation was used to dissect TBX5 transcriptional network in cardiac ventricular tissue. Overall, we identified 47 transcripts expressed under the control of TBX5, which may have contributed to the fatal arrhythmias in vTbx5KO mice. These included transcripts encoding for proteins implicated in cardiac conduction and contraction (Gja1, Kcnj5, Kcng2, Cacna1g, Chrm2), in cytoskeleton organization (Fstl4, Pdlim4, Emilin2, Cmya5), and cardiac protection upon stress (Fhl2, Gpr22, Fgf16). Interestingly, after TBX5 loss and arrhythmia development in vTbx5KO mice, TBX5 protein-level normalization by systemic adeno-associated-virus (AAV) 9 application, re-established TBX5-dependent transcriptome. Consequently, cardiac dysfunction was ameliorated and the propensity of arrhythmia occurrence was reduced. CONCLUSIONS: This study uncovers a novel cardioprotective role of TBX5 in the adult heart and provides preclinical evidence for the therapeutic value of TBX5 protein normalization in the control of arrhythmia.
AIMS: Arrhythmias and sudden cardiac death (SCD) occur commonly in patients with heart failure. We found T-box 5 (TBX5) dysregulated in ventricular myocardium from heart failure patients and thus we hypothesized that TBX5 reduction contributes to arrhythmia development in these patients. To understand the underlying mechanisms, we aimed to reveal the ventricular TBX5-dependent transcriptional network and further test the therapeutic potential of TBX5 level normalization in mice with documented arrhythmias. METHODS AND RESULTS: We used a mouse model of TBX5 conditional deletion in ventricular cardiomyocytes. Ventricular (v) TBX5 loss in mice resulted in mild cardiac dysfunction and arrhythmias and was associated with a high mortality rate (60%) due to SCD. Upon angiotensin stimulation, vTbx5KO mice showed exacerbated cardiac remodelling and dysfunction suggesting a cardioprotective role of TBX5. RNA-sequencing of a ventricular-specific TBX5KO mouse and TBX5 chromatin immunoprecipitation was used to dissect TBX5 transcriptional network in cardiac ventricular tissue. Overall, we identified 47 transcripts expressed under the control of TBX5, which may have contributed to the fatal arrhythmias in vTbx5KO mice. These included transcripts encoding for proteins implicated in cardiac conduction and contraction (Gja1, Kcnj5, Kcng2, Cacna1g, Chrm2), in cytoskeleton organization (Fstl4, Pdlim4, Emilin2, Cmya5), and cardiac protection upon stress (Fhl2, Gpr22, Fgf16). Interestingly, after TBX5 loss and arrhythmia development in vTbx5KO mice, TBX5 protein-level normalization by systemic adeno-associated-virus (AAV) 9 application, re-established TBX5-dependent transcriptome. Consequently, cardiac dysfunction was ameliorated and the propensity of arrhythmia occurrence was reduced. CONCLUSIONS: This study uncovers a novel cardioprotective role of TBX5 in the adult heart and provides preclinical evidence for the therapeutic value of TBX5 protein normalization in the control of arrhythmia.
Authors: Menno P Creyghton; Albert W Cheng; G Grant Welstead; Tristan Kooistra; Bryce W Carey; Eveline J Steine; Jacob Hanna; Michael A Lodato; Garrett M Frampton; Phillip A Sharp; Laurie A Boyer; Richard A Young; Rudolf Jaenisch Journal: Proc Natl Acad Sci U S A Date: 2010-11-24 Impact factor: 11.205
Authors: Alessandro D Mori; Yonghong Zhu; Ilyas Vahora; Brian Nieman; Kazuko Koshiba-Takeuchi; Lorinda Davidson; Anne Pizard; J G Seidman; Christine E Seidman; X Josette Chen; R Mark Henkelman; Benoit G Bruneau Journal: Dev Biol Date: 2006-05-24 Impact factor: 3.582
Authors: Malou van den Boogaard; L Y Elaine Wong; Federico Tessadori; Martijn L Bakker; Lisa K Dreizehnter; Vincent Wakker; Connie R Bezzina; Peter A C 't Hoen; Jeroen Bakkers; Phil Barnett; Vincent M Christoffels Journal: J Clin Invest Date: 2012-06-18 Impact factor: 14.808
Authors: Andreas Jungmann; Barbara Leuchs; Jean Rommelaere; Hugo A Katus; Oliver J Müller Journal: Hum Gene Ther Methods Date: 2017-10 Impact factor: 2.396
Authors: Katrin Wittköpper; Larissa Fabritz; Stefan Neef; Katharina R Ort; Clemens Grefe; Bernhard Unsöld; Paulus Kirchhof; Lars S Maier; Gerd Hasenfuss; Dobromir Dobrev; Thomas Eschenhagen; Ali El-Armouche Journal: J Clin Invest Date: 2010-01-11 Impact factor: 14.808
Authors: Pooja Agarwal; John N Wylie; Juan Galceran; Oksana Arkhitko; Cuiling Li; Chuxia Deng; Rudolf Grosschedl; Benoit G Bruneau Journal: Development Date: 2003-02 Impact factor: 6.868
Authors: Omar T Hammouda; Meng Yue Wu; Verena Kaul; Jakob Gierten; Thomas Thumberger; Joachim Wittbrodt Journal: PLoS One Date: 2021-12-17 Impact factor: 3.240